HealthMore in Health→
FDA Seeks More Data on Lilly’s Foundayo After Flagging Possible Safety Risks
Key Takeaways
- The FDA is asking Eli Lilly for additional data on Foundayo.
- The agency is evaluating potential risks tied to major cardiovascular events and liver damage.
- The request adds early scrutiny to a newly approved obesity medicine.
DE
DT Editorial Team··via endpoints.news